Shares of Nuformix plc (LON:NFX – Get Free Report) were up 10% during mid-day trading on Thursday. The company traded as high as GBX 0.11 and last traded at GBX 0.11. Approximately 1,072,582 shares traded hands during mid-day trading, a decline of 96% from the average session volume of 28,149,902 shares. The stock had previously closed at GBX 0.10.
Nuformix Stock Performance
The firm has a market capitalization of £2.87 million, a PE ratio of -3.75 and a beta of 1.53. The company’s 50-day moving average price is GBX 0.13 and its 200-day moving average price is GBX 0.18.
Nuformix Company Profile
Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis. It also has an option agreement with Oxilio Ltd. for NXP001 for oncology indications.
Recommended Stories
- Five stocks we like better than Nuformix
- Google’s Credit Backstop May Be TeraWulf’s Biggest Advantage
- Could the Midterms Revive Medicare for All? 3 Healthcare Stocks to Watch
- Qualcomm Beat Earnings, But Its Fastest-Growing Businesses Have a Catch
- Oil, Uranium, or Renewables? 3 Energy Plays for a Changing Market
Receive News & Ratings for Nuformix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuformix and related companies with MarketBeat.com's FREE daily email newsletter.
